Ansell Limited, a global leader in protection solutions, announces the acquisition of Sandel Medical Industries, LLC, a recognized leader in the development of staff and patient safety disposable products in the U.S. Ansell will continue the Sandel business under the Ansell Sandel Medical Solutions LLC name.
The Sandel product range covers six key product categories (sharps safety, ergonomic safety, medication handling & specimen handling, safety kits and safety products/correct site markers for patients) and presents an excellent opportunity for Ansell to expand our range of differentiated products.
The Sandel solutions portfolio will allow Ansell to offer hospitals and ambulatory surgery centers cost-effective solutions to improve safety of the environment of patients and staff and to comply with the ever increasing regulatory and legislative safety requirements for patients and staff.
Magnus Nicolin, CEO of Ansell Limited, comments, "The acquisition is an important step in Ansell's strategy to grow in both existing business segments, as well as to expand with integrated solutions in surgical safety. We are very excited about the Sandel opportunity and look forward to working with their experienced management team, staff, and valued customers."
The purchase price is $13.5 million and the purchase agreement includes sales and growth based earn-outs over the next five years.
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.